Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
Reports of psychiatric and vision problems with widely-used GLP-1 drugs warrant ongoing monitoring as millions of patients take these medications.
This pharmacovigilance study analyzes spontaneous adverse reaction reports for psychiatric and ophthalmic events associated with GLP-1 RAs in the context of their rapidly expanding use for diabetes and obesity. The signals—including suicidality and visual disturbances—require ongoing surveillance given the tens of millions of GLP-1 RA users globally.
What the study was
- Study design
- Pharmacovigilance analysis (spontaneous adverse reaction signals)
- Population
- Patients using semaglutide, liraglutide, and dulaglutide
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Naunyn-Schmiedeberg's archives of pharmacology
Why it surfaced
Safety signals for psychiatric/ophthalmic effects of widely-used GLP-1 RAs; important pharmacovigilance data for prescribers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.